Real-world treatment of allergic bronchopulmonary aspergillosis with tezepelumab
Treatments studied
Part of Immune system & allergy, Infections, Lungs & breathing clinical trials.
This study looks at how well the drug tezepelumab works in treating allergic bronchopulmonary aspergillosis (ABPA), a lung condition caused by an allergic reaction to a common fungus. It may help reduce asthma symptoms and flare-ups in people with severe asthma related to ABPA.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of ABPA based on specific criteria, including a positive skin test or blood test for Aspergillus allergy and high levels of IgE in your blood.
- You must have had severe asthma for at least 12 months, requiring high doses of inhaled steroids plus another asthma control medicine.
- You must have had at least 2 asthma attacks in the past year that needed treatment with steroid pills or injections.
- You must weigh more than 40 kg (about 88 pounds).
- You cannot have other major lung diseases like COPD or cystic fibrosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether benralizumab, a biologic medicine, works well in real-world settings for people with severe asthma caused by an allergic reaction to a common mold called Aspergillus. You may qualify if you have hard-to-control asthma despite strong medications and recent asthma flare-ups.
This study tests if biologic drugs are safe and effective for people with allergic bronchopulmonary aspergillosis (ABPA) who also have severe asthma. It may help if you've had an asthma attack in the past year.
This trial tests a procedure that uses a bronchoscope to clean mucus from the airways and then spray the antifungal drug amphotericin B directly into the lungs. It may help people whose ABPA is active and not improving with standard treatments.
This study tests a drug called tezepelumab for people with severe asthma that is not well controlled with current treatments. It aims to see if adding this drug can reduce asthma attacks and improve symptoms.
This trial tests if adding house dust mite allergy tablets (Acarizax) to tezepelumab (Tezspire) helps adults with severe allergic asthma stay in control. It is for people who are still struggling with asthma despite current treatments.
This trial tests if a drug called Tezepelumab can help adults with asthma who visit the emergency room. It aims to reduce severe asthma attacks and improve breathing control.
Hear when a new Allergic Bronchopulmonary Aspergillosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.